Vnitr Lek 2024, 70(8):508-512 | DOI: 10.36290/vnl.2024.097

Febrility in malignant disease

Štefan Sotak
I. interná klinika UN LP a UPJŠ LF v Košiciach

Fevers have many causes. The most common is infection. They can also occur in oncological diseases. Fevers caused directly by malignancy are called paraneoplastic. Their diagnosis can sometimes be very complex and lengthy and represents a therapeutic challenge even for an experienced physician; therefore they represent a non-negligible percentage of fevers of unknown origin. The so-called can be helpful naproxen test. Levels of inflammatory parameters can sometimes be misleading - they can be significantly elevated in active malignancy. In addition, febrility in an oncology patient can also occur due to infection, which arises as a result of malignant cachexia or febrile neutropenia, which arises as an adverse effect of chemotherapy, further iatrogenically (after radiation or after the administration of chemotherapeutic drugs), when the central nervous system is affected by primary malignancy or metastases, as part of an adrenal crisis during glucocorticoid treatment or after transfusion.

Keywords: febrility, neoplastic febrility, naproxen.

Accepted: November 27, 2024; Published: December 18, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sotak Š. Febrility in malignant disease. Vnitr Lek. 2024;70(8):508-512. doi: 10.36290/vnl.2024.097.
Download citation

References

  1. Malejčíková M. Telesná teplota a onkologické ochorenia. inVitro. 2021; 9(3):92-97.
  2. Horowitz HW. Fever of unknown origin or fever of too many origins? N Engl J Med. 2013; 368(3):197-199. Go to original source... Go to PubMed...
  3. Hrubišková K, Jeseňák M, Payer J. Čo sa skrýva za autoinflamáciou? Vnitř Lék. 2020; 66(3):e13-e21. Go to original source...
  4. Culver EL, Bateman AC. General principles of IgG4-related disease. Diag Histopatol. 2013;19(4):111-118. Go to original source...
  5. Feketeová J. Castlemanova choroba. inVitro. 2019; 7(1):116-123.
  6. Bodel P. Generalized perturbations in host physiology caused by localized tumors. Tumors and fever. Ann N Y Acad Sci. 1974;230:6-13. Go to original source... Go to PubMed...
  7. Bleeker-Rovers CP, Vos FJ, de Kleijn EMHA, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007; 86:26-38. Go to original source... Go to PubMed...
  8. Fernandes e Santana L, de Sousa Rodrigues M, de Araújo Silva MP, et al. Fever of unknown orign - a literature review. Rev Assoc Bras. 2019; 65(8):1109-1115. Go to original source... Go to PubMed...
  9. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13(11):870-877. Go to original source... Go to PubMed...
  10. Foggo V, Cavenagh J. Malignant causes of fever of unknown origin. Clin Med (Lond). 2015;15(3):292-294. Go to original source... Go to PubMed...
  11. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(6 Suppl):1684-1688. Go to original source...
  12. Preti HA, Cabanillas F, Talpaz M, et al. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med. 1997;127(3):186-194. Go to original source... Go to PubMed...
  13. Nehaj F, Mokáň M, Sokol J. Malígne lymfómy. inVitro. 2019; 7(1):98-103.
  14. Wongrakpanich S, Wongrakpanich A, Melhado K, et al. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018;9(1):143-150. Go to original source... Go to PubMed...
  15. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage. 1988;3(3):141-144. Go to original source... Go to PubMed...
  16. Koporcová J. Súčasná laboratórna diagnostika zápalových stavov. inVitro. 2015; 3(1):36-38.
  17. Wang C-S, Sun C-F. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32(5):471-482.
  18. Durnaś B, Wątek M, Wollny T, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets Therapy. 2016;9:469-475. Go to original source... Go to PubMed...
  19. Ichikawa K, Watanabe S, Miura S, et al. Prognostic significance of procalcitonin in small cell lung cancer. Transl Lung Cancer Res. 2022;11(1):43-52. Go to original source... Go to PubMed...
  20. Trimboli P, Giovanella L. Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Endocrinol Metab (Seoul). 2018; 33(2):204-210. Go to original source... Go to PubMed...
  21. Kajikawa S, Ohashi W, Kato Y, et al. Prognostic impact of serum procalcitonin in non-small cell lung cancer. Tumori. 2021;107(5):385-391. Go to original source... Go to PubMed...
  22. Ermayanti S, Afriani A, Firdaus DB. Tricky sepsis biomarker: Extremly high procalcitonin in squamous cell lung cancer with doubtful infection. Respirology Case Reports. 2023;11(10):e01210. Go to original source... Go to PubMed...
  23. Mechl Z, Brančíková D. Nežádoucí účinky protinádorové léčby a jejich léčba. Med Pro Praxi. 2009;6(6):325-329.
  24. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. Go to original source... Go to PubMed...
  25. Kennedy RH, Silver R. Neuroimmune Signaling: Cytokines and the CNS. In: Pfaff D, Volkow N. (eds) Neuroscience in the 21st Century. Springer: New York; 2015: 1-41. ISBN 978-1-4614-6434-1. Go to original source...
  26. Tingle LE, Molina D, Calvert CW. Acute pericarditis. Am Fam Physician. 2007; 76(10):1509-1514.
  27. Marks LB, Yu X, Vujaskovic Z, et al. Radiation-induced lung injury. Semin Radiat Oncol. 2003; 13(3):333-345. Go to original source... Go to PubMed...
  28. Jain N, Chauhan U, Kumar Puri S, et al. Fibrosing mediastinitis: when to suspect and how to evaluate? BJR|Case Reports. 2016; 2(1):20150274. Go to original source... Go to PubMed...
  29. Goodman RS, Johnson DB, Balko JM. Corticosteroids and Cancer Immunotherapy. Clin Cancer Res. 2023;29(14):2580-2587. Go to original source... Go to PubMed...
  30. Kašperová S, Tarabčáková L, Kašperová B, et al. Horúčka neznámeho pôvodu. Interná Med. 2020;20(3):123-127.
  31. Mulders-Manders C, Simon A, Bleeker-Rovers C. Fever of unknown origin. Clin Med (Lond). 2015;15(3):280-284. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.